News
The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Vividion Therapeutics and Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
Novartis’ gene therapy Zolgensma is again under a cloud of doubt after Nature Biotechnology retracted its 2010 article noting “issues” regarding data cited in a key figure in the report.
Merck and Moderna are moving forward with a personalized cancer vaccine as Merck exercised its option to develop and commercialize mRNA-4157/V940, the companies announced Wednesday.
This week, financing came in the form of loans, private placements and a Series B, throwing support behind an injectable heart failure drug, oral immunology therapies and an ASD treatment.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases.
In the wake of a global pandemic and economic downturn, the hiring market has turned on its head. BioSpace spoke with PharmaLogics Recruiting to learn how employers can stay competitive.
Incidence of gout - the most common inflammatory arthritis in the world - are on the rise. Arthrosi Therapeutics, Synlogic, Atom Bioscience and Ginkgo Bioworks are on the case with novel new approaches.
Forge Biologics’ novel gene therapy for Krabbe disease, a fatal neurodegenerative disorder, showed positive signals in a Phase I/II trial.
Albireo Pharma reported dazzling Phase III ASSERT data of Bylvay for Alagille syndrome (ALGS). The company is headed to U.S. and European regulators with expectations of regulatory filings in Q1 of 2023.
With $50 million in backing from Apple Tree Partners, Ascidian Therapeutics launches Tuesday with technology that allows for the treatment of some diseases through rewriting of RNA.